Lonza Group broke ground at Tuas Biomedical Park in Singapore for the new facility for its Cell Therapy business. The new facility will be adjacent to the company’s large-scale mammalian manufacturing facility.

Stefan Borgas, chief executive officer of Lonza, said, “This new Cell Therapy manufacturing facility is a next step in fulfilling our strategy to expand our capacity globally and our presence in Asia. Cell Therapy is expected to be one of the most important innovation drivers of modern medicine and this new facility reinforces Lonza’s leading position as a custom manufacturer of cellular therapeutics.”

Construction will begin early in 2010 and the facility is expected to begin manufacturing therapies within the first two suites by mid-2011. The facility is designed to accommodate additional suites built to meet customer demand. The total investment for the first phase will be approximately $28.5 million.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference